Loading...
Market
What will be the primary focus area of new clinical trials by Massive Bio and Foundation Medicine by end of 2025?
2
Resolution / Starting Odds
Breast Cancer • 25%
Lung Cancer • 25%
Colorectal Cancer • 25%
Other • 25%
Official announcements from Massive Bio or Foundation Medicine
Story
Massive Bio Partners with Foundation Medicine to Improve Cancer Clinical Trials at ESMO24
Sep 13, 2024, 12:09 PM
Biotech company Massive Bio has announced a partnership with Foundation Medicine to enhance clinical trial recruitment and enrollment, focusing on precision cancer care. The collaboration aims to address the low enrollment rates in cancer clinical trials by leveraging AI and genomic profiling. This partnership, highlighted at the ESMO24 conference, is seen as a pivotal step in developing solutions to the cancer clinical trial enrollment paradox, potentially allowing more patients to access advanced treatments.
View original story
Similar markets
Tumor-removal technologies • 25%
Cancer screening and early detection • 25%
Cancer treatment in underserved communities • 25%
Other • 25%
Lung Cancer • 25%
Breast Cancer • 25%
Colorectal Cancer • 25%
Other Cancer Type • 25%
Technology development for surgeons • 25%
Cancer screenings • 25%
Follow-up treatments • 25%
Other • 25%
Cancer • 25%
Neurological disorders • 25%
Infectious diseases • 25%
Other • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
Other • 25%
Lung cancer • 25%
Breast cancer • 25%
Colorectal cancer • 25%
Other • 25%
Genetic Testing • 25%
Health and Wellness • 25%
Data Licensing • 25%
Other • 25%
Novocure • 25%
AstraZeneca • 25%
Chinese Biotech Firms • 25%
Other • 25%
Lymphoma • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Other • 25%
Drug Discovery • 25%
Patient Care • 25%
Operational Efficiency • 25%
Regulatory Compliance • 25%
Cancer Treatment • 25%
Neurology Treatment • 25%
Immunology Treatment • 25%
Other Treatment • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
Breast Cancer • 25%
Other • 25%